These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 282937)

  • 1. Paraplegia following intrathecal cytosine arabinoside.
    Wolff L; Zighelboim J; Gale RP
    Cancer; 1979 Jan; 43(1):83-5. PubMed ID: 282937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study.
    Dunton SF; Nitschke R; Spruce WE; Bodensteiner J; Krous HF
    Cancer; 1986 Mar; 57(6):1083-8. PubMed ID: 3455842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
    Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
    Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraparesis following intrathecal cytosine arabinoside: a case report with neuropathologic findings.
    Breuer AC; Pitman SW; Dawson DM; Schoene WC
    Cancer; 1977 Dec; 40(6):2817-22. PubMed ID: 271037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal cytosine arabinoside-induced acute, rapidly reversible paralysis.
    Saleh MN; Christian ES; Diamond BR
    Am J Med; 1989 Jun; 86(6 Pt 1):729-30. PubMed ID: 2729330
    [No Abstract]   [Full Text] [Related]  

  • 7. High doses of cytosine arabinoside (HD-Ara-C) as reinforcement during remission of acute myeloid leukemia.
    Zittoun R; Marie JP; Pommier Y; Pochat L
    Med Pediatr Oncol; 1982; 10 Suppl 1():259-61. PubMed ID: 6962322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose cytosine arabinoside in acute non-lymphoblastic leukemia.
    Kumar L; Kochupillai V; Dua H
    Cancer; 1989 Feb; 63(3):415-8. PubMed ID: 2912519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy.
    Stacchini A; Demurtas A; Aliberti S
    Cytometry B Clin Cytom; 2012 Sep; 82(5):280-2. PubMed ID: 22539249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular toxicity from high-dose cytosine arabinoside.
    Ritch PS; Hansen RM; Heuer DK
    Cancer; 1983 Feb; 51(3):430-2. PubMed ID: 6571799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
    Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High dosage and intermediate dosage cytosine arabinoside in the treatment of secondary leukemias].
    Leitha T; Jäger U; Schwarzinger I; Bettelheim P; Hinterberger W; Neumann E; Korninger C; Kyrle PA; Haas O; Schlappack O
    Wien Klin Wochenschr; 1988 Aug; 100(15):509-14. PubMed ID: 3176503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy.
    Boesen P; Fallingborg J; Spaun E
    Acta Med Scand; 1988; 224(2):189-91. PubMed ID: 3166602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission induction in acute myelogenous leukemia using cytosine arabinoside synchronization: a Southwest Oncology Group Study.
    Steuber CP; Humphrey GB; McMillan CW; Vietti TJ
    Med Pediatr Oncol; 1978; 4(4):337-42. PubMed ID: 281596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute fatal myeloencephalopathy after combined intrathecal chemotherapy in a child with acute lymphoblastic leukemia.
    von der Weid NX; de Crousaz H; Beck D; Deonna T; Miklossy J; Janzer RC
    Med Pediatr Oncol; 1991; 19(3):192-8. PubMed ID: 2023567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy?
    van Prooijen HC; Muus P; Roelofs JM; Punt K
    Scand J Haematol; 1986 Jan; 36(1):123-6. PubMed ID: 3456631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.
    Friedman JH; Shetty N
    Mov Disord; 2001 May; 16(3):575-7. PubMed ID: 11391764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preliminary evaluation of adverse effects after administration of arabinoside cytosine (Ara-C) in high doses to children with acute myelogenous leukemia].
    Wysocki M; Kurylak A; Pilecki O; Balcar-Boroń A
    Acta Haematol Pol; 1994; 25(1):37-42. PubMed ID: 8209612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.